A Unique Mammalian Suspension Technology Enhances Scalable rAAV Production with Pro10 Cell Line

Revolutionizing Gene Therapy: Viralgen’s Pro10™ Cell Line for Efficient and Scalable Recombinant Adeno-Associated Virus Production

Viralgen’s Pro10™ cell line is a new technology that aims to improve the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. This proprietary mammalian suspension technology allows for robust and scalable production of rAAVs, addressing the challenges faced in large-scale manufacturing of AAV gene therapies.

The Pro10™ cells have been fully characterized and licensed for gene therapy development by other biopharma companies, making them a reliable foundation for a robust rAAV vector manufacturing process. Viralgen has successfully scaled up these cells to 2000L, demonstrating consistent and reproducible cell growth rates. They exhibit similar productivity in small and large-scale bioreactors and can produce different AAV serotypes, making them an essential component of Viralgen’s platform process for manufacturing AAV vectors.

The HEK293 derived animal component-free suspension Pro10™ cell line is described in full in the PDF, which highlights its ability to reduce process development time and costs. This innovative technology is a promising advancement in the field of gene therapy manufacturing, offering a solution to the challenges faced in large-scale production of AAV vectors. With its ability to produce high-quality rAAV vectors at scale, Viralgen’s Pro10™ cell line paves the way for groundbreaking gene therapies that could revolutionize medicine.

Leave a Reply

The NFL trade deadline has been extended until after Week 9. Previous post The NFL’s Trade Deadline Gets a Late Start: New Date Set for Week 9 of the 2024 Season
Trump’s Partnership with Truth Social Boosts Him Into the Ranks of the World’s 500 Wealthiest Individuals Next post Former President Donald Trump’s Net Worth Surges on Success of Truth Social Merger and Stock Market Gains